Subscribe

FDA Approves Fluciclovine F18 Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer

Urology Practice Management - June 2016, Vol 5, No 3 - FDA Approvals, News & Updates

On May 27, 2016, the FDA approved fluciclovine F18 (Axumin; Blue Earth Diagnostics) injection, a radioactive diagnostic imaging agent used to detect recurrent prostate cancer.

Fluciclovine F18 injection is indicated for use with positron emission tomography (PET) imaging in patients with suspected prostate cancer recurrence based on elevated prostate-specific antigen (PSA) levels.

“Imaging tests are not able to determine the location of the recurrent prostate cancer when the PSA is at very low levels,” said Libero Marzella, MD, PhD, Director of the FDA’s Center for Drug Evaluation and Research Division of Medical Imaging Products. “Axumin is shown to provide another accurate imaging approach for these patients.”

The FDA approval was based on 2 blinded studies evaluating the safety and efficacy of fluciclovine F18 injection. The first study compared 105 scans using fluciclovine F18 injection with histopathology obtained by prostate biopsy and by biopsies of suspicious imaged lesions in patients with suspected recurrence of prostate cancer. The second study compared the results from 96 scans using fluciclovine F18 injection with C11 choline scans, an approved PET scan imaging test, in men with a median PSA value of 1.44 ng/mL.

In both studies, onsite radiologists and 3 independent radiologists read the scans, and their conclusions were generally consistent with one another.

The most frequently reported adverse events were injection site pain, redness, and a metallic taste in the mouth.

Because fluciclovine F18 is a radioactive drug, the FDA recommends appropriate safety measures to limit exposure to patients and providers during administration.

Related Items
Rinvoq Approved for the Treatment of RA Refractory to Methotrexate
Rheumatology Practice Management October 2019 Vol 7 No 1 published on November 13, 2019 in FDA Approvals, News & Updates
FDA Approves Taltz for the Treatment of Ankylosing Spondylitis
Rheumatology Practice Management October 2019 Vol 7 No 1 published on November 13, 2019 in FDA Approvals, News & Updates
FDA Approves Rinvoq for the Treatment of RA Refractory to Methotrexate
Web Exclusives published on September 4, 2019 in FDA Approvals, News & Updates
Biosimilar Hadlima (Adalimumab-bwwd) Approved for Treatment of Rheumatic Diseases
Web Exclusives published on July 29, 2019 in FDA Approvals, News & Updates
FDA News - June 2018
Rheumatology Practice Management June 2018 Vol 6 No 3 published on June 20, 2018 in FDA Approvals, News & Updates
FDA Updates - February 2018
Rheumatology Practice Management February 2018 Vol 6 No 1 published on February 16, 2018 in FDA Approvals, News & Updates
New Treatments Approved for Patients with Giant-Cell Arteritis and Moderate-to- Severe Rheumatoid Arthritis
Rheumatology Practice Management June 2017 Vol 5 No 3 published on June 28, 2017 in FDA Approvals, News & Updates
Scott Gottlieb, MD, Appointed as New FDA Commissioner
Anne Rowe
Rheumatology Practice Management June 2017 Vol 5 No 3 published on June 28, 2017 in FDA Approvals, News & Updates
FDA Updates - October 2016
Rheumatology Practice Management October 2016 Vol 4 No 5 published on October 28, 2016 in FDA Approvals, News & Updates
Biosimilar to Etanercept FDA Approved for Inflammatory Diseases
Web Exclusives published on September 8, 2016 in FDA Approvals, News & Updates, In the News
Last modified: July 5, 2016
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search